Relay Therapeutics (RLAY) Accumulated Expenses (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Accumulated Expenses data on file, last reported at $20.9 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses changed 0.37% year-over-year to $20.9 million in Q1 2026; TTM through Mar 2026 was $20.9 million, a 0.37% change from a year earlier, with the FY2025 full-year figure at $13.6 million, down 35.75% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $20.9 million, up from $13.6 million in the prior quarter.
• Over the last five years, Accumulated Expenses for RLAY reached as high as $33.2 million in Q3 2024 and fell as low as $13.6 million in Q4 2025.
• Historically, Accumulated Expenses has averaged $23.5 million across 5 years, with a median of $22.7 million in 2022.
• Across the five-year window, Accumulated Expenses surged 84.3% in 2023 and tumbled 35.75% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $22.7 million in 2022, then plunged by 34.41% to $14.9 million in 2023, then soared by 42.62% to $21.2 million in 2024, then tumbled by 35.75% to $13.6 million in 2025, then surged by 53.26% to $20.9 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $20.9 million in Q1 2026, $13.6 million in Q4 2025, and $25.1 million in Q3 2025.